Olumiant Side Effects: What to Expect and When to Call Your Doctor

Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor that works by suppressing overactive immune signaling. While it can be very effective for rheumatoid arthritis and alopecia areata, its immune-modulating mechanism also means it comes with a significant safety profile that every patient should understand. This guide covers what side effects you might experience, which require medical attention, and how to monitor your health while on Olumiant.

Understanding Olumiant's Boxed Warnings

Olumiant carries the FDA's most serious warning — a boxed warning — for five categories of risk. These warnings apply to the entire class of JAK inhibitors and were largely derived from long-term studies in rheumatoid arthritis patients. Here's what the boxed warning covers:

Serious infections: Olumiant weakens your immune system, making you more susceptible to bacterial, viral, fungal, and opportunistic infections. Tuberculosis (TB), pneumonia, herpes zoster (shingles), urinary tract infections, and invasive fungal infections are among the most serious.

Malignancy: Olumiant may increase your risk of developing lymphoma, lung cancer, and non-melanoma skin cancers. This risk is higher in current or past smokers.

Major adverse cardiovascular events (MACE): Heart attack, stroke, and cardiovascular death are more likely in patients aged 50 or older with at least one cardiovascular risk factor, particularly current or former smokers.

Thrombosis: Deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial blood clots have been reported. Some cases were fatal.

Mortality: Overall death rates were higher in JAK inhibitor-treated patients compared to TNF inhibitor patients in a comparative safety study.

These warnings are real, but it's important to put them in context. The boxed warning data was primarily derived from a study of tofacitinib in patients aged 50+ with established RA who had at least one CV risk factor. Your individual risk may differ significantly depending on your age, smoking history, cardiovascular health, and the condition being treated.

Common Side Effects of Olumiant

The following side effects were reported in clinical trials at rates of 1% or greater. These are the ones you're most likely to experience:

Upper respiratory tract infections (16.3% at 2 mg): Colds, sinus infections, sore throats — these are the most common side effect. Most are mild.

Nausea: Reported in approximately 2.7% of patients at the 2 mg dose. Usually mild and improves with time or taking the medication with food.

Herpes simplex: Cold sores or genital herpes reactivation.

Herpes zoster (shingles): Reactivation of the chickenpox virus causing a painful rash.

Headache: Reported more commonly in alopecia areata clinical trials.

Acne: Reported in less than 1% of RA patients but more commonly in alopecia areata patients (as skin follicle activation is a JAK pathway side effect).

Elevated cholesterol (hyperlipidemia): Olumiant can raise LDL, HDL, and total cholesterol. Lipid monitoring at 12 weeks after initiation is recommended.

Elevated liver enzymes: Transient ALT/AST elevations. If suspected drug-induced liver injury, therapy should be interrupted.

Urinary tract infections (UTIs): More common than in placebo groups. Report symptoms early.

Serious Side Effects: When to Seek Emergency Care Immediately

Stop taking Olumiant and seek emergency care immediately if you experience:

Chest pain, shortness of breath, or sudden severe headache (possible heart attack or stroke)

Sudden leg swelling, pain, or redness (possible DVT or blood clot)

Hives, difficulty breathing, swelling of lips/tongue/throat (severe allergic reaction)

High fever with confusion, stiff neck, or altered consciousness (possible serious infection or meningitis)

When to Call Your Doctor (But Not an Emergency)

Call your doctor promptly (within 24 hours) if you experience:

Fever, chills, or flu-like symptoms that don't improve in 48 hours

Signs of shingles — burning, tingling, or a one-sided rash

Abdominal pain with fever and change in bowel habits (possible GI perforation)

New or worsening cough, weight loss, or night sweats (possible TB reactivation)

Jaundice (yellowing of skin/eyes) or dark urine (possible liver damage)

Routine Monitoring While on Olumiant

Your doctor should monitor the following labs before and during Olumiant therapy:

Complete blood count (CBC): To watch for low red blood cells (anemia), low white blood cells (neutropenia), and low lymphocytes

Liver function tests (ALT/AST): To detect drug-induced liver injury

Lipid panel: At approximately 12 weeks post-initiation, then periodically

TB screening: Before starting and periodically during therapy

The Bottom Line on Side Effects

Olumiant's side effect profile is significant, but manageable for most patients with proper monitoring. The majority of patients in clinical trials tolerated baricitinib well — upper respiratory infections were the most common complaint, and serious events were less frequent. Keep all your monitoring appointments, know the warning signs, and communicate openly with your prescriber. For information on drugs that interact with Olumiant, read our guide on Olumiant drug interactions. And if you're having trouble finding your Olumiant prescription, medfinder can help you locate it at a specialty pharmacy near you.